Shanghai Medicilon vs RemeGen Co. Ltd. A: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Shanghai Medicilon Inc (688202.CG)

Q3 202610 Jul – 24 Aug 2026

▲4

Medicilon swings to profit as CRO demand recovers

Medicilon turns profitable in H1 2026 Medicilon reported first-half net profit of 51.6 million yuan, reversing a year-ago loss, with revenue up 40.9% to 761 million yuan and cash flow up 80.5%. This confirms the company's own turnaround, directly supporting the stock price.
This is the single most important new fact: the company itself became profitable, validating the recovery story.
Global innovative drug R&D demand is recovering Medicilon and peer Innostar both said global demand for innovative drug research is recovering, with solid order backlogs and higher capacity use. This means more business and better pricing ahead, pushing the stock up.
It explains the underlying force behind the profit swing and is a fresh confirmation from the actual half-year reports.
Sector-wide CRO earnings surge lifts sentiment WuXi AppTec's first-half profit topped 10 billion yuan and peers like Joinn and BioMap forecast huge gains, triggering limit-up moves across CRO stocks. Medicilon rose over 13% on the coattails, as investors bet on the whole sector.
It shows the powerful sector momentum that is pulling Medicilon's stock price up alongside its own results.
Rising lab monkey prices boost CRO profits The price of cynomolgus monkeys, a key cost for some CROs, climbed to 178,000 yuan, helping drive big profit forecast increases for companies like Joinn and Medicilon. Higher prices can signal strong demand and support margins.
It is a specific new driver behind the profit upgrades that readers may not know about.

August 202610 Jul – 24 Aug 2026

▲4

Medicilon swings to profit as CRO demand recovers

Medicilon turns profitable in H1 2026 Medicilon reported first-half net profit of 51.6 million yuan, reversing a year-ago loss, with revenue up 40.9% to 761 million yuan and cash flow up 80.5%. This confirms the company's own turnaround, directly supporting the stock price.
This is the single most important new fact: the company itself became profitable, validating the recovery story.
Global innovative drug R&D demand is recovering Medicilon and peer Innostar both said global demand for innovative drug research is recovering, with solid order backlogs and higher capacity use. This means more business and better pricing ahead, pushing the stock up.
It explains the underlying force behind the profit swing and is a fresh confirmation from the actual half-year reports.
Sector-wide CRO earnings surge lifts sentiment WuXi AppTec's first-half profit topped 10 billion yuan and peers like Joinn and BioMap forecast huge gains, triggering limit-up moves across CRO stocks. Medicilon rose over 13% on the coattails, as investors bet on the whole sector.
It shows the powerful sector momentum that is pulling Medicilon's stock price up alongside its own results.
Rising lab monkey prices boost CRO profits The price of cynomolgus monkeys, a key cost for some CROs, climbed to 178,000 yuan, helping drive big profit forecast increases for companies like Joinn and Medicilon. Higher prices can signal strong demand and support margins.
It is a specific new driver behind the profit upgrades that readers may not know about.

Latest10 Jul – 24 Aug 2026

▲4

Medicilon swings to profit as CRO demand recovers

Medicilon turns profitable in H1 2026 Medicilon reported first-half net profit of 51.6 million yuan, reversing a year-ago loss, with revenue up 40.9% to 761 million yuan and cash flow up 80.5%. This confirms the company's own turnaround, directly supporting the stock price.
This is the single most important new fact: the company itself became profitable, validating the recovery story.
Global innovative drug R&D demand is recovering Medicilon and peer Innostar both said global demand for innovative drug research is recovering, with solid order backlogs and higher capacity use. This means more business and better pricing ahead, pushing the stock up.
It explains the underlying force behind the profit swing and is a fresh confirmation from the actual half-year reports.
Sector-wide CRO earnings surge lifts sentiment WuXi AppTec's first-half profit topped 10 billion yuan and peers like Joinn and BioMap forecast huge gains, triggering limit-up moves across CRO stocks. Medicilon rose over 13% on the coattails, as investors bet on the whole sector.
It shows the powerful sector momentum that is pulling Medicilon's stock price up alongside its own results.
Rising lab monkey prices boost CRO profits The price of cynomolgus monkeys, a key cost for some CROs, climbed to 178,000 yuan, helping drive big profit forecast increases for companies like Joinn and Medicilon. Higher prices can signal strong demand and support margins.
It is a specific new driver behind the profit upgrades that readers may not know about.

RemeGen Co. Ltd. A (688331.CG)

Q3 202614 Jul – 7 Aug 2026

▲4

RemeGen's profit turnaround and new drug list inclusion drive gains

Essential medicines list inclusion RemeGen's innovative drugs were added to China's 2026 National Essential Medicines List, which should boost sales volume and long-term standardized treatment. This expands the patient base and supports revenue growth.
This is a new regulatory catalyst that directly increases demand for RemeGen's products.
Share buyback plan RemeGen announced a 25-50 million yuan share buyback, part of a broader wave of central enterprise buybacks. This signals management confidence and can support the stock price by reducing shares outstanding.
It shows insider confidence and provides a capital market support mechanism.
Profit turnaround expected RemeGen expects first-half 2026 net profit of about 4.7 billion yuan, swinging from a loss to a profit. This significant improvement reflects strong business performance and boosts investor confidence.
It is a major financial milestone that directly impacts valuation and sentiment.
Sector momentum and licensing deals Innovative drug stocks rallied, with sector out-licensing deals reaching $99.7 billion in H1 2026. RemeGen's improved results were highlighted, drawing investor attention to the sector's growth potential.
It shows broader industry tailwinds that can lift RemeGen's stock through increased sector investment.

July 202614 Jul – 7 Aug 2026

▲4

RemeGen's profit turnaround and new drug list inclusion drive gains

Essential medicines list inclusion RemeGen's innovative drugs were added to China's 2026 National Essential Medicines List, which should boost sales volume and long-term standardized treatment. This expands the patient base and supports revenue growth.
This is a new regulatory catalyst that directly increases demand for RemeGen's products.
Share buyback plan RemeGen announced a 25-50 million yuan share buyback, part of a broader wave of central enterprise buybacks. This signals management confidence and can support the stock price by reducing shares outstanding.
It shows insider confidence and provides a capital market support mechanism.
Profit turnaround expected RemeGen expects first-half 2026 net profit of about 4.7 billion yuan, swinging from a loss to a profit. This significant improvement reflects strong business performance and boosts investor confidence.
It is a major financial milestone that directly impacts valuation and sentiment.
Sector momentum and licensing deals Innovative drug stocks rallied, with sector out-licensing deals reaching $99.7 billion in H1 2026. RemeGen's improved results were highlighted, drawing investor attention to the sector's growth potential.
It shows broader industry tailwinds that can lift RemeGen's stock through increased sector investment.

Latest14 Jul – 7 Aug 2026

▲4

RemeGen's profit turnaround and new drug list inclusion drive gains

Essential medicines list inclusion RemeGen's innovative drugs were added to China's 2026 National Essential Medicines List, which should boost sales volume and long-term standardized treatment. This expands the patient base and supports revenue growth.
This is a new regulatory catalyst that directly increases demand for RemeGen's products.
Share buyback plan RemeGen announced a 25-50 million yuan share buyback, part of a broader wave of central enterprise buybacks. This signals management confidence and can support the stock price by reducing shares outstanding.
It shows insider confidence and provides a capital market support mechanism.
Profit turnaround expected RemeGen expects first-half 2026 net profit of about 4.7 billion yuan, swinging from a loss to a profit. This significant improvement reflects strong business performance and boosts investor confidence.
It is a major financial milestone that directly impacts valuation and sentiment.
Sector momentum and licensing deals Innovative drug stocks rallied, with sector out-licensing deals reaching $99.7 billion in H1 2026. RemeGen's improved results were highlighted, drawing investor attention to the sector's growth potential.
It shows broader industry tailwinds that can lift RemeGen's stock through increased sector investment.